Chemomab Therapeutics (CMMB) Cash from Investing Activities (2017 - 2023)

Chemomab Therapeutics (CMMB) has 7 years of Cash from Investing Activities data on file, last reported at $1.7 million in Q4 2023.

• Quarterly Cash from Investing Activities fell 81.56% year-over-year to $1.7 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $15.9 million (down 18.71% YoY) and the FY2025 annual result came in at $5.4 million, up 134.65% from the prior year.
• Cash from Investing Activities fell to $1.7 million in Q4 2023, from $4.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $14.4 million in Q1 2023 to a low of -$20.6 million in Q2 2021.
• A 5-year average of -$496550.0 and a median of -$6500.0 in 2020 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2021 — Cash from Investing Activities plunged 652600.0% — and 2022, when it jumped 119200.0%.
• Tracing CMMB's Cash from Investing Activities over 5 years: stood at $251000.0 in 2019, then slumped by 101.2% to -$3000.0 in 2020, then sank by 652600.0% to -$19.6 million in 2021, then soared by 147.75% to $9.4 million in 2022, then tumbled by 81.56% to $1.7 million in 2023.
• The last three Cash from Investing Activities figures came in at $1.7 million (Q4 2023), $4.0 million (Q3 2023), and -$4.3 million (Q2 2023), per Business Quant data.